Biotech Values

[biomaven0]

Thanks Jim.

On the SARM, if the "outcomes" is something easily measurable like muscle strength compared with placebo, then that would I think be feasible. If it's some vaguer or longer term outcome (like mortality or becoming bedridden) then I think prospective partners would flinch. I think the FDA has become a little less doctrinaire, and I could see them approving based on a significant increase in lean muscle mass.

We do know that lack of lean body mass in the elderly is a significant predictor of increased mortality. Indeed having a minimum thigh circumference is perhaps the single best biometric prediction of longevity in adults. (Fat thighs turn out to be fine!).



http://www.bmj.com/content/339/bmj.b3292

Here's a discussion of the regulatory issue surrounding cachexia:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4670733/